This Phase 3 trial (DeLLphi-304) evaluated patient-reported outcomes (PROs) with tarlatamab versus standard-of-care chemotherapy in adults with extensive-stage small cell lung cancer (ES-SCLC) following platinum-based chemotherapy.
The full paper text was not provided, so specific PRO instrument results, response rates, and absolute numeric outcomes cannot be extracted or verified.
Explore related topics
